- Home
- NEGG vs INZY Comparison
NEGG vs INZY Comparison
Compare NEGG & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- INZY
- Stock Information
- Founded
- NEGG 2001
- INZY 2015
- Country
- NEGG United States
- INZY United States
- Employees
- NEGG N/A
- INZY N/A
- Industry
- NEGG Other Specialty Stores
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- INZY Health Care
- Exchange
- NEGG Nasdaq
- INZY Nasdaq
- Market Cap
- NEGG 180.8M
- INZY 188.2M
- IPO Year
- NEGG 2010
- INZY 2020
- Fundamental
- Price
- NEGG $0.43
- INZY $1.36
- Analyst Decision
- NEGG
- INZY Strong Buy
- Analyst Count
- NEGG 0
- INZY 8
- Target Price
- NEGG N/A
- INZY $17.75
- AVG Volume (30 Days)
- NEGG 948.3K
- INZY 784.0K
- Earning Date
- NEGG 08-29-2024
- INZY 03-11-2025
- Dividend Yield
- NEGG N/A
- INZY N/A
- EPS Growth
- NEGG N/A
- INZY N/A
- EPS
- NEGG N/A
- INZY N/A
- Revenue
- NEGG $1,391,833,000.00
- INZY N/A
- Revenue This Year
- NEGG $6.01
- INZY N/A
- Revenue Next Year
- NEGG N/A
- INZY N/A
- P/E Ratio
- NEGG N/A
- INZY N/A
- Revenue Growth
- NEGG N/A
- INZY N/A
- 52 Week Low
- NEGG $0.39
- INZY $1.32
- 52 Week High
- NEGG $1.32
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- NEGG 38.37
- INZY 20.27
- Support Level
- NEGG $0.40
- INZY $1.32
- Resistance Level
- NEGG $0.48
- INZY $3.18
- Average True Range (ATR)
- NEGG 0.05
- INZY 0.27
- MACD
- NEGG 0.00
- INZY -0.15
- Stochastic Oscillator
- NEGG 27.20
- INZY 2.15
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.